Medtech Trends 2026: How Global Forces Are Reshaping Medical Technology

Executive Summary

The medical technology (medtech) industry is entering a period of accelerated transformation. As 2026 approaches, structural forces across pricing, care delivery, supply chains, clinical pathways, and enabling technologies are redefining how companies compete and where growth will occur. This analysis, drawn from Clarivate's "Medtech Trends to Watch in 2026," examines five pivotal trends: the expansion of volume-based procurement in Mainland China, the continued migration of procedures to outpatient settings, the rise of supply chain resilience as a strategic imperative, the disruptive impact of GLP-1 therapies on metabolic care pathways, and the shift toward platform-based competition powered by enabling technologies. Together, these trends highlight a global industry adapting to new economic realities, evolving patient needs, and an increasingly interconnected healthcare ecosystem.

Introduction

The medtech sector stands at the crossroads of technological innovation and global economic change. For years, medical device companies focused on product performance and clinical outcomes. Today, they must also navigate complex pricing mechanisms, geopolitical trade tensions, and rapid shifts in care delivery. The year 2026 promises to be a watershed moment, with forces both inside and outside the industry reshaping the competitive landscape. This article explores the key medtech market trends identified by industry analysts and their implications for businesses, healthcare providers, and patients worldwide.

Background

Historically, medtech success depended on bringing safe, effective devices to market and securing reimbursement from payers. However, the past decade has witnessed an increasing convergence of healthcare and technology, as well as the globalization of medical device markets. In particular, the rise of digital health, robotics, and data-driven care has opened new opportunities and challenges. At the same time, governments are seeking to control healthcare costs, leading to innovative procurement policies and a shift toward value-based care. Against this backdrop, the five trends outlined below are expected to shape medtech strategy in the coming year.

Main Analysis

1. Mainland China’s VBP Expansion Is Redefining Global Market Economics

Mainland China's volume-based procurement (VBP) program has evolved from a cost-containment measure into a powerful market-structuring mechanism. The latest national VBP round introduces more sophisticated anchor-price logic, deeper price compression, and allocation systems that favor domestic manufacturers. While originally designed to expand patient access and curb high device costs, the program now influences pricing expectations and competitive positioning in markets well beyond China.

For multinational medtech companies, VBP is no longer a localized policy. It has become a benchmark for price and volume negotiations in other emerging markets and even in developed economies. The program is accelerating domestic innovation by giving local companies a larger share of the market while forcing international players to rethink their portfolio strategies, cost structures, and long-term commitment to China.

Why it matters: VBP is fundamentally altering the economics of global medtech. Companies that wish to participate in one of the world's largest healthcare markets must adapt to a new reality in which price, volume, and local competition are in constant flux. The ripple effects are likely to influence global pricing strategies and R&D investment decisions for years to come.

2. Outpatient and ASC Settings Are Becoming Central to Procedure Strategy

The migration of procedures from hospitals to outpatient settings is accelerating, driven by both clinical innovation and payment policy. The U.S. Centers for Medicare & Medicaid Services (CMS) 2026 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Payment System Final Rule expands the ASC Covered Procedure List and phases out the inpatient-only list. This opens the door for higher-acuity procedures, including cardiac ablation, to be performed in lower-cost settings when clinically appropriate.

This is not a new trend, but its scope is expanding. Orthopedics, general surgery, and other specialties have long used ASCs as growth drivers. Now, more complex procedures are being added, requiring medtech companies to adapt their commercial models, product designs, and economic value propositions. Devices must be designed for smaller footprints, shorter procedure times, and different workflows. Reimbursement strategies must account for facility fees and patient out-of-pocket costs.

Why it matters: As care shifts toward outpatient sites of service, the entire value chain of medtech—from sales force deployment to clinical training to service and support—must be reconfigured. Companies that understand the unique needs of ASCs will gain a competitive edge, while those tied to traditional hospital-based models may struggle.

3. Global Trade and Supply Chain Pressures Are Reshaping Manufacturing Strategy

The medtech industry is not immune to the global supply chain disruptions that have affected virtually every manufacturing sector. Tariff exposure, geopolitical tensions, and fluctuating material costs are challenging assumptions about where and how devices should be produced. In response, companies are diversifying sourcing, re-evaluating business strategies, and pursuing more flexible multi-region manufacturing footprints.

Large manufacturers are using their scale, integration, and technology investments to buffer against volatility. This may further consolidate market power among the biggest players, as smaller companies struggle to absorb rising costs. At the same time, supply chain resilience is becoming a key differentiator and a boardroom-level concern. The ability to trace components, ensure redundancy, and respond quickly to disruptions is now as important as product performance.

Why it matters: Cost structures, supplier concentration, manufacturing geography, and portfolio rebalancing will increasingly influence competitive advantage. Medtech companies must treat supply chain as a strategic asset, not just a logistical function. In an era of geopolitical uncertainty, resilience is a source of value for customers and investors alike.

4. GLP-1 Therapies Are Shifting Patient Behavior and Reshaping Care Pathways

The rapid adoption of glucagon-like peptide-1 (GLP-1) receptor agonists for weight management is one of the most notable developments in healthcare. While bariatric surgery remains the most effective intervention for substantial weight loss, GLP-1s have expanded the treatment landscape for metabolic disease. This is changing referral patterns, altering patient expectations, and influencing demand across adjacent medtech categories.

The impact is not uniform. Certain bariatric procedures are experiencing sharper volume pressure than others. Downstream effects are emerging in diabetes care, sleep apnea, cardiovascular monitoring, and other areas that are influenced by weight-related comorbidities. The GLP-1 effect reflects a broader shift in how metabolic disease is managed, moving from invasive interventions to a continuum of care that includes pharmaceutical, device, and digital health solutions.

Why it matters: The rise of GLP-1 therapies is not just a pharmaceutical phenomenon. It has profound implications for medtech companies that serve the obesity, diabetes, and related markets. Understanding the evolving clinical pathways and patient behavior is essential for forecasting demand and aligning product development with the new reality of metabolic care.

5. Enabling Technologies Are Driving the Shift Toward Platform-Based Competition

Across medtech, enabling technologies such as robotics, imaging, navigation, and digital workflow software are transforming how companies differentiate themselves. These technologies are no longer adjuncts to procedures; they are becoming central to integrated ecosystems that support clinical planning, surgical execution, and postoperative care.

Leading companies are investing heavily in platform architectures that anchor entire service lines, strengthen customer relationships, and unlock data-driven value propositions. Emerging open-platform systems are expanding flexibility and creating new competitive dynamics. The convergence of sensing, computing, and connectivity is enabling devices to serve as nodes in a larger digital health network, generating real-world evidence and personalizing treatment pathways.

Why it matters: Platform-based competition redefines how medtech companies deliver value and create long-term strategic advantage. Success will increasingly depend on the ability to build and manage ecosystems, not just standalone products. This shift will require new capabilities in software development, data analytics, and partnerships with technology companies and healthcare providers.

Global Perspective

These five trends are global in nature, albeit with regional variations. China's VBP is a prominent example of how procurement policy can reshape markets and influence global pricing. The migration to outpatient settings is most advanced in the United States, but similar dynamics are emerging in Europe and Asia as payers seek efficiency. Supply chain pressures affect every region, prompting reshoring and nearshoring strategies in North America, Europe, and Asia-Pacific. GLP-1 therapies are rapidly becoming a worldwide phenomenon, with implications for obesity treatment and public health. Enabling technologies are being adopted at varying speeds, with leading centers of excellence in the U.S., Europe, and Asia driving innovation.

The intersection of these trends highlights the interconnectedness of global healthcare. A policy decision in Beijing or Washington can reverberate across continents. Medtech companies must therefore adopt a globally aware, locally adaptable strategy. This requires deep knowledge of regulatory and reimbursement landscapes, supply chain dependencies, and clinical practice patterns in key markets.

Key Insights

• Pricing and market access are central to strategy: VBP and similar initiatives are forcing medtech companies to reconsider how they price, promote, and allocate resources in emerging markets.
• Site-of-care shifts create opportunities: The move to outpatient settings favors solutions that reduce procedure costs, improve throughput, and enable minimally invasive techniques.
• Supply chain robustness is non-negotiable: Companies that invest in diversified manufacturing, digital traceability, and agile logistics will be better positioned to withstand global disruptions.
• Therapeutic convergence is blurring boundaries: GLP-1 therapies illustrate how pharmaceutical innovations can disrupt device markets, compressing the historical separation between drug and device strategies.
• Platform ecosystems drive loyalty: Customers will increasingly choose partners that offer integrated solutions with seamless data flow, rather than single point products.

Future Outlook

Looking ahead to 2026 and beyond, the medtech industry will likely continue its evolution toward value-based, technology-driven care. The five trends examined here are not fleeting; they are structural shifts that will shape the industry's trajectory well into the next decade.

• Artificial intelligence will play an expanding role in surgical planning, real-time guidance, and predictive analytics, further blending medtech with digital health.
• Sustainability will become a key procurement criterion, pressuring companies to redesign products and packaging for circularity.
• Demographic change will drive demand for devices that address chronic diseases and an aging population, while also reshaping labor markets and healthcare workforce dynamics.
• International collaboration and regulatory harmonization will be critical to ensuring that innovation reaches patients safely and equitably.

Medtech companies that embrace these trends with a global mindset and a commitment to evidence-based innovation will be well positioned to thrive. Those that cling to outdated models may find themselves increasingly marginalized.

Conclusion

The medtech landscape in 2026 is defined by complexity and opportunity. From China's evolving procurement policies to the expansion of outpatient facilities, from supply chain realignments to the rise of GLP-1 therapies and platform-based competition, the industry is adapting to a new healthcare reality. These changes are not merely commercial; they affect how patients access care, how providers deliver treatment, and how societies invest in health. For industry observers, the lesson is clear: the future of medical technology will be shaped not only by scientific breakthroughs, but by economic, political, and social forces that demand a holistic, global perspective.